To evaluate the effect of an expanded gestational diabetes mellitus (GDM) screening strategy on perinatal outcomes.

This retrospective cohort study included gravidas screened for GDM at a single academic center. The "before" cohort (estimated due dates (EDD) March 2018-April 2019) was screened using the standard 2-step method. The "after" cohort (EDD November 2019-July 2023) was screened using an expanded strategy that included the potential for GDM diagnosis based on 1-2 weeks of home glucose monitoring following isolated fasting hyperglycemia on the 3-hour glucose tolerance test (GTT). The primary outcomes were primary cesarean delivery (PCD) and neonatal intensive care unit (NICU) admission. Binomial regression and Kruskal Wallis tests were used to compare perinatal outcomes between the two cohorts in the general population and in a subgroup of those with isolated fasting hyperglycemia.

Outcomes for the "before" cohort (n = 1,733) were compared with those in the "after" cohort (n = 6,280). In the general population, A2GDM incidence increased after expansion of the screening protocol (4.8% vs. 6.4%, RR 1.34, 95% CI 1.07-1.69), but PCD and NICU admission rates were unchanged. In the subgroup of patients with isolated fasting hyperglycemia (n = 233), there was a significant increase in the incidence of any GDM (12.5 vs. 46.0%, RR 3.68, 95% CI 1.95-6.93) and A2GDM (8.3% vs. 37.3%, RR 4.47, 95% CI 2.03-9.87). There was no difference in PCD between cohorts, but NICU admission increased significantly in the "after" cohort (8.3% vs 22.4%, RR 2.68, 95% CI 1.18-6.08) in this subgroup.

An expanded approach to GDM diagnosis using home blood glucose monitoring following isolated fasting hyperglycemia on 3-hour GTT was associated with increased A2GDM incidence but no improvements in primary maternal or neonatal outcomes. In the absence of clinical benefit, we do not recommend widespread implementation of this expanded strategy.

To assess the usability and acceptability of nurse-led telemonitoring in managing gestational diabetes among Nepalese women.

We conducted a convergent mixed-method study among 91 pregnant women diagnosed with gestational diabetes at Dhulikhel Hospital, Nepal. Participants received glucometers and blood pressure monitors, along with training and instructions to measure and record their blood pressure and glucose levels at home once a week. Starting from the 28th gestational week, the study nurse reviewed measurements obtained at home during the biweekly telemonitoring follow ups, alternating with hospital visits. We used the System Usability Scale (SUS) to assess perceived usability and conducted in-depth interviews to understand participants' experiences with telemonitoring and related technologies, including feasibility, acceptability, satisfaction with treatment, usability, as well as any difficulties or unmet needs. The quantitative analysis included descriptive statistics to summarize participant characteristics and System Usability Scale (SUS) responses, while a framework analysis was applied to examine the qualitative data.

The mean SUS score for telemonitoring services was 72.1 ± 7.6, indicating good usability (a score ≥ 68 indicates good usability). 93% of participants wanted to use the service frequently; 88% found it easy to use; 81% considered it well-integrated with their typical prenatal care. Participants acknowledged the benefits of virtual health visits, such as frequent health monitoring, facilitation of communication with healthcare providers, appointment reminders, added motivation for home monitoring, increased access to health information, and prevention of unnecessary anxiety. Overall, participants expressed satisfaction with the quality and features of the nurse-led telemonitoring for managing gestational diabetes, emphasizing its role in ensuring uninterrupted prenatal care.

Telemonitoring is a feasible and acceptable tool to facilitate close monitoring of pregnant women with gestational diabetes in peri-urban hospital settings in Nepal.

The prevalence of gestational diabetes mellitus (GDM) is currently on the rise globally, which heightens the risk of adverse pregnancy outcomes and subsequently increases the likelihood of cesarean delivery. GDM can induce hyperglycemic conditions in cesarean wounds, leading to delayed wound healing and complications such as itching, pain, and scarring. These complications significantly impact the quality of life and mental health of mothers. Furthermore, there is a lack of effective clinical prevention strategies. Consequently, the need to improve wound healing after cesarean sections in women with GDM is a pressing concern that warrants our attention. To maximize the therapeutic impact and extend the bioavailability of calycosin-7-glucoside (CG), it was integrated into a hybridized hydrogel (GOHA) as a drug carrier to create the GOHACG hydrogel. Bases on our tests, the GOHACG hydrogel demonstrated a strong capacity for water absorption, appropriate pore size, and good biocompatibility to adjust to the in situ surroundings of the wound. GOHACG also promoted epidermal regeneration, collagen deposition, angiogenesis, and the conversion of macrophages from the M1 to M2 phenotype. Indicating a reduction in the inflammatory response, accelerated wound repair, and minimized skin scarring in a postcesarean delivery model involving gestational diabetic mellitus mice. In brief, the GOHACG possesses significant properties that enhance wound healing in GDM model, suggesting its potential effects in treating wound healing of GDM.

Gestational diabetes mellitus (GDM) and preeclampsia (PE) are common and serious disorders of pregnancy that threaten maternal safety and perinatal outcomes. Generally, GDM is recognized as an independent risk factor for the development of preeclampsia, while a history of preeclampsia in primiparous women is also a risk factor for GDM in subsequent pregnancies. However, the intricate underlying mechanisms of GDM and PE remain elusive. This study developed a diagnostic prediction model for GDM and PE. It investigated the correlation between shared signature genes and immune infiltration characteristics, by employing bioinformatic analysis combined with a machine learning strategy. The microarray datasets GSE103552 and GSE74341 from the Gene Expression Omnibus (GEO) database were used to obtain differentially expressed genes (DEGs). Then, signature genes were identified from the common DEGs via the methods of random forest (RF) algorithms, and artificial neural network (ANN) models. Furthermore, the immune infiltration patterns associated with GDM and PE were explored and validated in the training and testing sets. Moreover, to uncover the molecular mechanisms involved, an mRNA-miRNA network of target genes was constructed, and potential therapeutic drugs for GDM and PE were explored by querying the Connectivity Map (CMap) database. We obtained 45 DEGs by intersecting upregulated and downregulated DEGs from the GSE103552 and GSE74341 datasets. The results of GO annotation indicated that these 45 DEGs were mainly enriched in the process of cell cycle, and KEGG enrichment analysis indicated significant associations with immune signal transduction pathways and immune-related infectious disease. Six signature genes, namely TRA2A, NPM3, PHF5A, SNORD1C, PLXNA3, and C14orf142, were determined by machine learning models, and a diagnostic prediction model for GDM and PE was constructed based on these key genes, validating the highest prediction in the testing set. Moreover, we found increased infiltration of iDCs and T cell co-inhibition in the GDM group, while neutrophil, Th2 cell, and HLA levels were found to have decreased significantly. The PE group showed a significant increase in mast cells. In addition, the identified key genes were found to have potential associations with various immunocytes, immune functions, and checkpoints in the training and testing sets. Then, a miRNA-gene network analysis predicted several key miRNAs-miR-204, miR-23abc, miR-9, miR-205, and miR-455-5p-that might play significant roles in regulating these DEGs. In addition, the research also identified four potential therapeutic compounds for GDM (prima-1-met, geranylgeraniol, MLN-8054, and LY-364947), along with other drugs (deferiprone, peucedanin, MPEP, and IWR-1-endo) that could be targeted for treating PE. In summary, this work identified six signature genes (TRA2A, NPM3, PHF5A, SNORD1C, PLXNA3, and C14orf142) as potential genetic biomarkers for the diagnostic prediction of GDM and PE. A diagnostic prediction model was constructed based on these key genes, demonstrating strong performance when validated with an independent dataset. Moreover, we investigated the similarities and differences between the two diseases in terms of immune infiltration landscape and analyzed the correlations between key genes and the immune infiltration landscape, which provided insights into the molecular mechanisms underlying the development of GDM and PE. This understanding could pave the way for breakthroughs in identifying new immunotherapeutic targets and strategies for disease prevention and treatment.

Maternal obesity associates with an increased risk of offspring neurodevelopmental disorders. Although the underlying mechanism(s) remain unclear, evidence suggests a role for altered DNA methylation. We utilized a murine model of diet-induced obesity to investigate the impact of maternal obesity on the offspring brain transcriptome and DNA methylation. C57Bl/6 dams were fed high-fat high-sugar (HFD, n = 7) or control (CON, n = 7) diets. Maternal obesity/hyperglycemia associated with offspring growth restriction, with brain-sparing specifically in females. Postnatal hypoglycemia was seen in HFD males, but not females. The 3' RNA-sequencing revealed perturbations in metabolic and cell differentiation pathways in neonatal male and female offspring frontal cortex and cerebellum. Compared with controls, HFD males, but not females, had lower cortical and cerebellar DNMT gene and protein expression, and reduced cerebellar TET enzyme mRNA. Whilst female offspring had lower cerebellar 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) than males, there were no effects of HFD on 5mC/5hmC in cortex or cerebellum in either sex. Our data suggest that maternal obesity has sex-specific effects on fetal neurodevelopment, including enzymes involved in DNA methylation/demethylation. These mechanisms may play a role in the increased risk of neurodevelopmental disorders following obese/diabetic pregnancies, including increased male susceptibility to these disorders.

To assess the relationship between perinatal factors, and echocardiographic left ventricular (LV) dimensions after delivery in infants who are large for gestational age (LGA).

This prospective cohort study that was conducted between 2014 and 2018, and involved healthy LGA newborns born ≥ 35 weeks' gestation, delivered at New York-Presbyterian Brooklyn Methodist Hospital, and a control group of appropriate for gestational age (AGA) infants. Data were analyzed using multivariate linear regression in STATA.

A total of 563 neonates were enrolled in this study. They were composed of 414 AGA infants as the control group and 149 LGA infants as the intervention group. Males were predominant in both groups. A larger proportion of neonates were admitted to the neonatal intensive care unit (NICU) in LGA infants (74.6%) as compared to the AGA infants (33.5%) (p < 0.001). Regression analysis identified birth weight (BW) as a key factor, positively correlating with increased LVmass, interventricular septum thickness, and LV posterior wall thickness in both LGA and AGA infants. Additionally, BW showed a positive correlation with left ventricular internal dimensions in diastole and systole. Higher maternal BMI was associated with an increase in fractional shortening in LGA infants, while maternal insulin use during pregnancy was positively associated with interventricular septum thickness. Notably, male infants exhibited significantly higher LV internal dimensions in both diastole and systole, while GA negatively impacted the left ventricular mass index.

The study's findings underscore the significant influence of perinatal factors on neonatal cardiac morphology in both LGA and AGA infants. Certain perinatal variables were identified as key determinants affecting various aspects of LV structure. These insights highlight the importance of considering these perinatal factors in neonatal cardiac assessments for early detection and intervention.

A successful pregnancy relies on the precise regulation of the maternal immune system to recognize and tolerate the allogeneic fetus, while simultaneously preventing infection. Immune checkpoint molecules (ICMs), such as programmed death receptor 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), T cell immunoglobulin, and mucin-domain containing-3 (Tim-3), play critical roles in regulating the immune response during pregnancy. Emerging research highlights the therapeutic potential of targeting these molecules to restore the immune balance in complicated pregnancies. Understanding the dynamic regulation of ICMs during pregnancy may provide new insights into the pathogenesis of these conditions and offer novel approaches for clinical interventions. Here, we review the expression patterns and functions of key ICMs at the maternal-fetal interface, and their involvement in maintaining immune tolerance throughout gestation. Additionally, we describe the current understanding of immune checkpoint pathways in the pathogenesis of complicated pregnancies and discuss the potential for therapeutic targeting of these pathways in this setting.

Gestational diabetes mellitus (GDM) is a metabolic disorder posing significant risks to maternal and infant health, with a lack of effective early screening markers. Therefore, identifying early screening biomarkers for GDM with higher sensitivity and specificity is urgently needed.

High-throughput sequencing was employed to screen for key circular RNAs (circRNAs), which were then evaluated using reverse transcription quantitative polymerase chain reaction. Logistic regression analysis was conducted to examine the relationship between clinical characteristics, circRNA expression, and adverse pregnancy outcomes. The diagnostic accuracy of circRNAs for early and mid-pregnancy GDM was assessed using receiver operating characteristic curves. Pearson correlation analysis was utilized to explore the relationship between circRNA levels and oral glucose tolerance test results. A predictive model for early GDM was established using logistic regression.

Significant alterations in circRNA expression profiles were detected in GDM patients, with hsa_circ_0031560 and hsa_ circ_0000793 notably upregulated during the first and second trimesters. These circRNAs were associated with adverse pregnancy outcomes and effectively differentiated GDM patients, with second trimester cohorts achieving an area under the curve (AUC) of 0.836. In first trimester cohorts, these circRNAs identified potential GDM patients with AUCs of 0.832 and 0.765, respectively. The early GDM prediction model achieved an AUC of 0.904, validated in two independent cohorts.

Hsa_circ_0031560, hsa_circ_0000793, and the developed model serve as biomarkers for early prediction or midterm diagnosis of GDM, offering clinical tools for early GDM screening.

Investigate the association between Oral Glucose Tolerance Test (OGTT) after in vitro fertilization (IVF) treatment and adverse maternal and neonatal outcomes in twin pregnancies.

This retrospective study encompassed 2,541 twin pregnancies conceived through IVF treatment. Adverse maternal and neonatal outcomes were compared across different subgroups based on individual and combined OGTT classifications. A Spearman correlation regression model examined associations between OGTT levels at different time points and parameters such as gestational age, birth weight, and length. Subsequently, a Logistic regression model with restricted cubic splines (RCS) explored the relationships between OGTT levels at different time points and adverse pregnancy outcomes. Ultimately, nine types of machine learning models were developed using OGTT glucose values at different times to predict the risk of adverse pregnancy outcomes.

In subgroup analysis based on individual OGTT diagnosis, three time points were examined: fasting glucose (OGTT0), 1-hour post-glucose (OGTT1), and 2-hour post-glucose (OGTT2). OGTT0 ≥ 5.1 mmol/L was significantly associated with increased risks of ICP and neonatal hypoglycemia (p = 0.031; p = 0.022). OGTT1 ≥ 10 mmol/L correlated with higher risks of ICP and neonatal hyperbilirubinemia (p = 0.001; p = 0.002). OGTT2 ≥ 8.5 mmol/L was also linked to neonatal hyperbilirubinemia (p < 0.001). In combined impaired OGTT subgroups, the impaired fasting glucose (IFG) group had a higher incidence of neonatal hypoglycemia than the impaired glucose tolerance (IGT) group and IFG & IGT group, but a lower risk of neonatal hyperbilirubinemia. OGTT2 was negatively correlated with gestational age at delivery (β = - 0.08, p = 0.018), and both OGTT1 and OGTT2 were negatively correlated with neonatal birth weight (β = - 10.54, p = 0.008; β = - 15.04, p < 0.001), as well as OGTT2 with birth length (β = - 0.16, p = 0.009). The RCS logistic regression model indicated that the increase OGTT values was associated with the ICP risk, and the relationship between OGTT2 and neonatal hyperbilirubinemia was U-shaped. Among the various machine learning models predicting adverse outcomes, RandomForest exhibited superior performance.

OGTT values in twin pregnancies under IVF treatment are closely linked to adverse maternal and neonatal outcomes, with post-load glucose levels potentially serving as an early biomarker for identifying poorer outcomes. The inflection points in the RCS suggest a new indication point for the association between OGTT and adverse pregnancy outcomes in twin pregnancies conceived through IVF.

Maternal pre-pregnancy diabetes is associated with a higher risk of adverse pregnancy outcomes. Few large, cohort studies have assessed associations with a wide large range of causes of infant death.

This retrospective cohort study included all singleton live births to women aged 18-49 years in the US National Vital Statistics System from 2011 to 2020. Multivariable Poisson regression models were used to estimate adjusted relative risks (RRs) with 95% confidence intervals (CIs) for all-cause and cause-specific infant mortality.

Of 34  918  803 pregnant women with singleton live births, 302  823 had pre-pregnancy diabetes with 3585 corresponding infant deaths [estimated mortality rate per 10 000 infants with 95% CI was 78.60 (75.96-81.25)] compared with 34  615  980 without pre-pregnancy diabetes and 171  989 corresponding infant deaths [42.63 (42.41-42.86)]. The adjusted RR (95% CI) of pre-pregnancy diabetes compared with no pre-pregnancy diabetes was 1.84 (1.78-1.91) for infant death, 1.89 (1.81-1.97) for neonatal death, 1.85 (1.77-1.94) for early neonatal death, 2.04 (1.87-2.23) for late neonatal death, and 1.75 (1.65-1.86) for postneonatal deaths. The association was stronger (RR: 2.03, 95% CI: 1.88-2.20) with lower maternal age (<25 years) than with higher maternal age (≥40 years) (RR: 1.44, 95% CI: 1.28-1.63). Associations varied across maternal race, smoking, and body mass index. Significantly increased risk was observed for 48 out of 73 specific causes of death.

Our findings confirm that maternal pre-pregnancy diabetes is an important risk factor for infant death, encompassing a wide range of causes of death, and suggest that these effects may be systemic given the large number of specific causes of death affected.

To elucidate risk factors associated with adverse perinatal outcomes in early-gestational diabetes mellitus (GDM).

A dataset of 385 early-GDM cases from a prospective cohort was analyzed. Early-GDM was diagnosed if one or more of the following criteria were met: fasting plasma glucose (PG) levels of 92-125 mg/dL, 1-h PG levels ≥180 mg/dL, and 2-h PG levels ≥153 mg/dL during a 75-g oral glucose tolerance test before 20 weeks of gestation. Multivariate analysis was used to examine associations between candidate risk factors and a composite outcome of maternal and neonatal adverse events.

Pre-pregnancy overweight/obesity (pre-pregnancy body mass index [BMI] ≥25.0 kg/m2) was significantly associated with a higher risk of the composite outcome compared with normal weight (pre-pregnancy BMI of 18.5-24.9 kg/m2), an adjusted risk ratio (aRR) of 1.44 (95% confidence interval [CI]: 1.08-1.93), and an adjusted risk difference (aRD) of 13.6% (95% CI: 2.6-24.6%). Compared with fasting PG levels below 92 mg/dL, levels between 95 and 125 mg/dL were associated with a significantly higher risk of the composite outcome, with an aRR and aRD of 1.42 (95% CI: 1.01-1.99) and 12.9% (95% CI: 0.3-25.5%), respectively.

Early-GDM, combined with pre-pregnancy overweight/obesity and/or fasting PG levels of 95-125 mg/dL, is associated with a higher risk of adverse perinatal outcomes and should be prioritized for intervention.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that increases the risk of gestational diabetes mellitus (GDM). This study aims to assess the correlation between PCOS and GDM and to identify associated healthcare needs.

A mixed-methods approach was used. The retrospective study analyzed 2635 medical records of women aged 19-45 who underwent fertility treatments (2020-2023). The prospective study (2023-2024) assessed PCOS and GDM knowledge, nutrition, and physical activity among three groups: PCOS, GDM, and normal pregnancies.

Women with PCOS had a significantly higher BMI (p < 0.001) and an increased risk of GDM (28.1% vs. 10.6%, p < 0.001), with a 2.94-fold higher likelihood (95% CI: 2.22-3.90). Preterm birth (p = 0.029) and multiple pregnancies (p = 0.014) were also more common. The GDM group demonstrated better nutritional habits (p = 0.017), while the PCOS group showed higher physical activity levels (p < 0.001). Greater disease knowledge correlated with healthier behaviors.

PCOS is a strong risk factor for GDM and adverse pregnancy outcomes. Targeted education and lifestyle interventions are crucial for improving maternal and neonatal health. Future research should focus on long-term metabolic management in women with PCOS.

The racial/ethnic disparities in the prevalence of obesity, diabetes, and adverse birth outcomes such as preterm delivery indicate that it is essential to account for the varying risks associated with pregnant women of different races and ethnics during clinical prenatal examinations. However, the racial and ethnic disparities in how pre-pregnancy diabetes in mothers relates to preterm birth as well as the combined association of maternal diabetes and pre-pregnancy obesity with preterm birth remain unclear. In this study, we aimed to 1) examine the racial/ethnic disparities in the association of maternal diabetes including gestational diabetes mellitus (GDM) and pre-pregnancy diabetes with preterm birth 2) and the racial/ethnic disparities in the joint associations of maternal diabetes and pre-pregnancy obesity with preterm birth.

In this population-based cohort study, we included 17,027,792 mothers documented in the National Vital Statistic System in the U.S. from 2016 to 2020. All these data were analyzed in 2021. Maternal pre-pregnancy diabetes was defined as having diabetes diagnosed prior to this pregnancy, and GDM was defined as having newly diagnosed diabetes in this pregnancy. Pre-pregnancy BMI (kg/m2) was classified as underweight (< 18.5 kg/ m2), normal weight (18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), obesity class I (30.0-34.9 kg/m2), obesity class II (35.0-39.9 kg/m2), and obesity class III (≥ 40 kg/m2). Preterm birth, defined as delivery occurring at less than 37 weeks of gestation, was the main outcome of interest. We further categorized preterm birth into three subtypes: extremely (< 28 weeks), very (28-31 weeks), and moderately (32-36 weeks) preterm birth. Logistic regression models were used for association analyses in this study.

Among 17,027,792 mothers (mean age: 29.4 ± 5.4 years), 1,374,286 (8.07%) mothers delivered a preterm infant. Women with pre-pregnancy diabetes had the highest risk of preterm birth followed by women with GDM overall and across all racial/ ethnic groups. However, from pre-pregnancy underweight to obesity III, the magnitude of the association between pre-pregnancy diabetes and preterm birth decreased for non-Hispanic Black women (underweight, 4.47 [3.34-5.99], normal weight 4.28 [3.98-4.60], overweight 3.29 [3.11-3.49], obesity I 3.09 [2.93-3.26], obesity II 2.98 [2.82-3.16], obesity III 3.19 [3.04-3.35]), while it showed an increasing trend for non-Hispanic Asians ( underweight 1.45 [0.91-2.30], normal weight 2.16 [1.90-2.47], overweight 2.71 [2.47-2.97], obesity I 3.10 [2.82-3.41], obesity II 3.58 [3.13-4.09], obesity III 3.99 [3.34-4.77]). The corresponding OR was (underweight 4.33 [3.21-5.83], normal weight 3.69 [3.47-3.93], overweight 3.26 [3.10-3.42], obesity I 3.33 [3.19-3.49], obesity II 3.47 [3.29-3.65], obesity III 3.89 [3.68-4.11]) among Hispanics and (underweight 5.17 [4.34-6.17], normal weight 5.01 [4.83-5.21], overweight 4.98 [4.80-5.17], obesity I 4.66 [4.48-4.85], obesity II 4.58 [4.38-4.79], obesity III 4.50 [4.31-4.69]) among non-Hispanic White. Comprehensive analysis of the association between diabetes, pre-pregnancy diabetes, obesity, ethnicity, and preterm birth found that compared to white women with normal weight and normal blood glucose levels, any other racial\ethnic group has an elevated risk of preterm birth, particularly when accompanied by unhealthy weight, GDM, or pre-pregnancy diabetes. Specifically, non-Hispanic Black individuals with normal blood sugar levels (1.69 [1.67-1.70]) have a higher risk of preterm birth than non-Hispanic White individuals with GDM (1.37 [1.35-1.40]). Similarly, Asian pregnant women with class 2 and class 3 obesity (1.72 [1.65-1.78], 1.96 [1.83-2.10]), as well as Hispanic pregnant women with class 2 and class 3 obesity (1.46 [1.44-1.48], 1.64 [1.61-1.67]), also have a higher risk of preterm birth than white women with GDM 1.37 [1.35-1.40].

In conclusion, while both pre-pregnancy diabetes and GDM were significantly associated with preterm birth, the associations varied by race/ethnicity. The risk of preterm birth for GDM increased with increasing BMI in all race/ethnicity groups. However, the pattern of the joint association of pre-pregnancy diabetes and BMI levels with preterm birth differed by race/ethnicity. Future studies on the underlying mechanisms of the racial/ethnic disparities in the association of diabetes and obesity with preterm birth are needed.

Gestational diabetes mellitus (GDM) is best managed via lifestyle changes. We aimed at investigating to which extent women with GDM adhered to dietary recommendations and to which extent an impact was observed on the glycaemic control compared to women without GDM.

Women with overweight/obesity (n = 349) were recruited in early pregnancy. GDM was diagnosed with a 2-h oral glucose tolerance test in mid-or-early pregnancy (median 25.9 and 14.7 gestational weeks). Dietary assessments included an index of dietary quality (good ≥ 10 and poor < 10/15 scores) and 3-day food-diaries with nutrient intake calculated and dietary patterns identified. Glucose and insulin concentrations were analysed from blood samples collected in late pregnancy (after GDM diagnosis).

Women with GDM (n = 98) followed more often a healthier dietary pattern (62.2%) than women without GDM (49.0%, p < 0.05), but no difference in good dietary quality was seen (53% vs. 59.8%, p = 0.071). While the majority of women with GDM adhered to some recommendations, 51% to carbohydrate, 54.1% to total fat and 69.4% to sucrose, only 16.3% adhered to the protein and 4.1% to the fibre intake recommendations. Women with GDM had lower adherence to protein, total fat and fibre recommendations but higher adherence to that of sucrose than women without GDM (p < 0.05). A good dietary quality was associated with lower insulin and HOMA2-IR values (p < 0.05).

Adherence to dietary recommendations, particularly fibre and protein intake, is unsatisfactory in women with GDM. Overall dietary quality is related to better control of glucose metabolism proposing a target for dietary counselling.

Gestational diabetes mellitus (GDM) is increasingly becoming a serious public health challenge. Innovative, effective and scalable lifestyle interventions to support women with GDM to manage their condition and prevent adverse obstetric and neonatal outcomes as well as later morbidity are required. This study aims to evaluate whether a novel, multilingual and scalable mobile health (mHealth) intervention (SPARK; SmartPhone App for gestational diabetes patients suppoRting Key lifestyle behaviours and glucose control) can improve self-management and treatment of GDM and prevent adverse maternal and offspring outcomes.

SPARK is a multicentre two-arm randomised controlled trial recruiting women diagnosed with GDM in south-eastern Sweden. A total of 412 women will be randomised to either standard care (control) or the SPARK intervention. The SPARK online platform (accessed through a mobile app) provides a behaviour change programme for healthy eating, physical activity and glycaemic control. To increase reach, SPARK is available in Swedish, English, Arabic and Somali. SPARK also comes with a clinician portal where healthcare professionals monitor and intervene when glycaemic control is unsatisfactory (above certain cut-offs). Primary outcomes are glycaemic control that is, time in range and HbA1c, while diet, physical activity (ActiGraph), gestational weight gain, metabolic and inflammatory biomarkers in weeks 37-38, adherence to protocol for daily glucose sampling, as well as adverse obstetric and neonatal outcomes are secondary outcomes. Secondary outcomes also include cardiometabolic risk evaluation, physical activity and healthy eating behaviours 1 year postpartum. A health economic evaluation of SPARK vs standard care will also be conducted.

This study has been approved by the Swedish Ethical Review Authority (2021-06627-01; 2022-03842-02; 2023-05911-02). Results will be disseminated through scientific papers in peer-reviewed journals, posts in traditional and social media, and presentations at scientific and healthcare professionals' conferences.

This trial was registered at the ClinicalTrials.gov register platform (ID NCT05348863) 27 April 2022.

The placenta has a central function in fetal glucose supply and placental volume has received rising awareness as a potential predicting factor for adverse pregnancy outcomes. We aimed to examine whether placental volume is a prognostic marker for metabolic perturbations affecting both mother and child. Data from 100 women participating in a longitudinal cohort study of healthy pregnant women were obtained. Placental volume was assessed via transabdominal ultrasound at gestational weeks 12-14. Additional ultrasound measurements were conducted at gestational weeks 23-25, 28-30, and 34-36 to assess fetal anthropometry. HbA1c was measured in first trimester blood samples. Both cross-sectional and prospective associations between first trimester placental volume and selected fetal and maternal parameters were examined using multivariable linear regression models. Interactions by gender were observed for associations with HbA1c, anterior abdominal wall thickness (AAWT), gestational weight gain and estimated fetal weight. A higher first trimester placental volume was related to higher HbA1c levels in the first trimester, higher AAWT measures in the third trimester, and greater gestational weight gain in women carrying a male fetus only (all p = 0.02). In women carrying a female fetus, a positive association was observed between placental volume and estimated fetal weight at gestational week 34-36 (p = 0.045). None of the other maternal or fetal parameters were related to placental volume (p ≥ 0.1). Our results indicate first trimester placental volume to be a potential prognostic factor for maternal glucose metabolism and both fetal and maternal anthropometric perturbations particularly for those mothers carrying a male fetus.

Objective: This study is aimed at evaluating maternal birth weight, recorded in Japan's Maternal and Child Health Handbooks, as a predictor for large for gestational age (LGA) neonates compared to traditional pregnancy factors. Methods: In this retrospective study, we analyzed maternal and neonatal data from 374 singleton, full-term pregnancies at Keiju General Hospital (2017-2020). Maternal birth weight was obtained from Japan's Maternal Child Health Handbooks, and fasting plasma glucose was measured during the 75-g oral glucose tolerance test (OGTT). Logistic regression models assessed the predictive contributions of maternal birth weight and fasting plasma glucose, adjusted for maternal and pregnancy factors. Results: Among 374 patients, 9.8% of neonates were classified as LGA. This group had a higher proportion of a family history of diabetes (p = 0.04) and greater maternal height (p = 0.01), pre-pregnancy weight (p = 0.004), weight before delivery (p = 0.03), and maternal birth weight (p = 0.001) than the non-LGA group. Multivariate analysis showed that maternal birth weight remained a significant predictor of neonatal birth weight after adjusting for other risk factors (odds ratios: 2.92 for maternal birth weight between 3500 and 3999 g and 4.77 for birth weight ≥ 4000 g). Conclusion: This study suggests the potential of incorporating maternal birth weight to improve LGA risk prediction. These findings provide foundational data for further research into the integration of maternal birth weight in risk assessment models and its potential clinical applications.

Studies on healthcare providers' experiences in screening and managing Gestational Diabetes Mellitus (GDM) are rare in northern Ghana. Understanding the experiences of healthcare providers in the screening and management of GDM has the potential to identify best practices to improve GDM care. Hence, this study sought to explore the experiences of healthcare providers in screening and managing GDM.

This was a qualitative study of five key informants involved in the screening and management of GDM, specifically an obstetrician, a dietician/nutritionist, a nurse, and two midwives in the northern region of Ghana. Face-to-face interviews were conducted with the aid of an interview guide, and the data were analysed via thematic analysis. We ensured trustworthiness through reflexivity, member checking, peer-debriefing, providing rich text, and keeping an audit trail.

Two main themes and six subthemes were generated. The first theme was resource-centred experiences, which explored events at the Antenatal Care (ANC) and the challenges in GDM screening and management, with subthemes namely: ANC setups, inadequate resources, and non-compliance. The second theme was care-centred experiences, which explored patient emotions during GDM care, and the care they receive post-GDM diagnosis, with subthemes namely: raw emotions, non-pharmacological therapy, and pharmacotherapy.

Findings suggest the need for health system strengthening through the training and recruitment of dedicated skilled personnel, as well as government intervention through policy revision to cover the cost of GDM diagnostic tests. Healthcare providers should also consider the psycho-emotional impact of diagnosis when managing GDM. The findings could be relevant for health policy, planning, advocacy, and social and behaviour change communication aimed at effective screening and management of GDM.

Maternal hyperglycemia is linked to adverse neonatal outcomes. However, current evidence was insufficient for mechanistic pathways. We aim to use two-sample Mendelian randomization (MR) to obtain a comprehensive understanding of the causal association and mediation pathways.

Genetic variants of fasting glucose (FG), insulin sensitivity index (ISI), glycated haemoglobin (HbA1c), gestational diabetes mellitus (GDM) and type 2 diabetes (T2D) were used as instruments (N = 50 404-898 130). The associations with offspring birthweight, gestational duration, spontaneous preterm and post-term birth were assessed by the inverse-variance weighted method, using summary statistics of European genome-wide association studies (N = 131 279-210 248). Sensitivity analyses, including multivariable MR removing pleiotropic effect from maternal body mass index (BMI), assessed the robustness. Mediation via placental weight and maternal hypertension were assessed via a two-step MR design.

FG (0.46 SD per mmol/L, 95% confidence interval [95% CI]: 0.32, 0.61) and GDM liability (0.18 SD per log odds, 95% CI: 0.08, 0.18) were positively associated with birthweight, with consistent findings for HbA1c, T2D liability and ISI. These associations were mediated by placental weight (proportion mediated: 32.8% to 77.7%). Higher HbA1c, GDM and T2D liability were associated with preterm birth (odds ratios for GDM: 1.07, 95% CI: 1.01, 1.14) and shorter gestational duration, whilst the association for T2D attenuated after adjusted for maternal BMI and gestational hypertension.

Maternal hyperglycemia is associated with higher birthweight (possibly indicating macrosomia), mediated via increased placental growth. GDM and T2D liability are related to preterm birth, whilst the association for T2D liability is driven by maternal adiposity.

Women with first trimester fasting glycaemia (FTFG) 92-125 mg/dL may present with normal 24-28th week OGTT (2T-OGTT). Predictors of persistent hyperglycaemia were scarcely investigated. We studied the prevalence and predictors of gestational diabetes mellitus (GDM) in the 2T-OGTT in women with untreated elevated FTFG.

Retrospective study of women from the national GDM registry with FTFG between 92 and 125 mg/dL that had passed unnoticed and untreated until the 2T-OGTT.

GDM in the 2T-OGTT. Women with and without GDM were compared. A multivariate logistic regression analysis was used to study GDM predictors. Included variables: FTFG, newborn sex, and known GDM risk factors.

We studied 407 women. 82% (82.1%) of women had a positive 2T-OGTT. Women with abnormal 2T-OGTT were older, had higher BMI, and more often carried female newborns. There were no differences concerning other known GDM risk factors, FTFG, and obstetric or neonatal complications. Age, BMI and newborn sex were associated with higher risk of GDM independently of other GDM risk factors or FTFG. Per 1 year of age and 1 kg/m2 of BMI, the OR (95%CI) for this association were 1.10 (1.05-1.16) and 1.07 (1.02-1.12), respectively. Alternatively, women older than 35 years or with a BMI ≥ 30Kg/m2 had an OR of 2.53 (1.30-4.90) and 2.20 (1.22-3.98), respectively. Women with male newborns had approximately half the risk of abnormal 2T-OGTT [OR 0.51 (0.30-0.87)].

Nearly 18% of women with FTFG between 92 and 125 mg/dL had a normal 2T-OGTT. Older age, higher BMI, and female newborns were associated with increased risk of abnormal 2T-OGTT.

Gestational Diabetes Mellitus (GDM) prevalence is rising worldwide, but optimal dietary strategies remain unclear. The eMOM pilot RCT compared a plant-protein rich Healthy Nordic Diet (HND) and a moderately carbohydrate restricted diet (MCRD) and their potential effects on time in glucose target range (≤ 7.8 mmol/L, %TIR), and on newborn body composition.

Forty-two participants were randomized to either HND (n = 20) or MCRD (n = 22) face-to-face nutritional counseling from gestational weeks (GW) 24 + 0-28 + 6 (baseline) until delivery. The HND intervention had no restriction in carbohydrate intake and emphasized plant-based protein sources and Nordic food, while the MCRD had a moderate carbohydrate restriction (~ 40% in proportion to total daily energy consumption, E%). Continuous glucose monitoring was worn for 14 days to assess glucose levels and %TIR. Blood samples for glucose and lipid metabolism and 3-day food diaries were collected at baseline and at GW 34 + 0-35 + 6. Neonatal body composition was measured by air displacement plethysmography. Difference between groups were analysed with t-test and Wilcoxon test.

Thirty-two women completed the study. Both groups maintained the %TIR during majority of the time (98.9 and 99.3% for MCRD and HND respectively, p = 0.921) in GW 34 + 0 - 35 + 6. The mean glucose was lower in the MCRD group compared to the HND group (5.0 SD 1.03 vs. 5.2 SD 0.96 mmol/l, p < 0.001). No differences were observed in glucose variability, lipid metabolism, gestational weight gain, or in the body composition of the newborns. HND had lower diet macronutrient adherence than the MCRD, resulting in similar macronutrient composition in both groups. The mean macronutrient intakes were fat: 40.6 vs. 39.5 E%, carbohydrate: 40.5 vs. 42.4 E%, protein: 18.9 vs. 18.1 E% for the MCRD and HND groups, respectively. The HND decreased intake of meat and increased fish consumption significantly compared to the MCRD.

Both a moderately restricted carbohydrate diet and a diet focused on plant-based protein effectively maintained a large time within the treatment target range in women with GDM. Further research could explore the impact of protein quantity and sources in maternal diets on glycemic control and newborn outcomes.

The eMOM pilot trial is registered in Clinicaltrials.gov (21/09/2018, NCT03681054).

Preterm birth (PTB) is a leading cause of neonatal mortality, particularly in sub-Saharan Africa where 40% of global neonatal deaths occur. We identified and combined demographic, clinical, and psychosocial correlates of PTB among Kenyan women to develop a risk score.

We used data from a prospective study enrolling HIV-negative women from 20 antenatal clinics in Western Kenya (NCT03070600). Depressive symptoms were assessed by study nurses using the Center for Epidemiologic Studies Depression Scale (CESD-10), intimate partner violence (IPV) with the Hurt, Insult, Threaten, Scream scale (HITS), and social support using the Medical Outcomes Survey scale (MOS-SSS). Predictors of PTB (birth < 37 weeks gestation) were identified using multivariable Cox proportional hazards models, clustered by facility. We used stratified k-fold cross-validation methods for risk score derivation and validation. Area under the receiver operating characteristic curve (AUROC) was used to evaluate discrimination of the risk score and Brier score for calibration.

Among 4084 women, 19% had PTB (incidence rate: 70.9 PTB per 100 fetus-years (f-yrs)). Predictors of PTB included being unmarried (HR:1.29, 95% CI:1.08-1.54), lower education (years) (HR:0.97, 95% CI:0.94-0.99), IPV (HITS score ≥ 5, HR:1.28, 95% CI:0.98-1.68), higher CESD-10 score (HR:1.02, 95% CI:0.99-1.04), lower social support score (HR:0.99, 95% CI:0.97-1.01), and mild-to-severe depressive symptoms (CESD-10 score ≥ 5, HR:1.46, 95% CI:1.07-1.99). The final risk score included being unmarried, social support score, IPV, and MSD. The risk score had modest discrimination between PTB and term deliveries (AUROC:0.56, 95% CI:0.54-0.58), and Brier Score was 0.4672. Women considered "high risk" for PTB (optimal risk score cut-point) had 40% higher risk of PTB (83.6 cases per 100 f-yrs) than "low risk" women (59.6 cases per 100 f-ys; HR:1.6, 95% CI:1.2-1.7, p < 0.001).

A fifth of pregnancies were PTB in this large multi-site cohort; PTB was associated with several social factors amenable to intervention. Combining these factors in a risk score did not predict PTB, reflecting the multifactorial nature of PTB and need to include other unmeasured factors. However, our findings suggest PTB risk could be better understood by integrating mental health and support services into routine antenatal care.

To investigate the effect of D-chiro inositol (DCI) supplementation on perinatal outcomes in pregnant women at high risk of gestational diabetes mellitus (GDM), we conducted a prospective, randomized, placebo-controlled study. Eligibility criteria included women aged ≥ 35 years old, with a pre-pregnancy body mass index ≥ 24 kg/m2, having a family history of type 2 diabetes, having a history of GDM, polycystic ovary syndrome, or a history of delivering macrosomia infants. Participants who were recruited at a gestational age of 12-16 weeks, were randomly to receive either DCI 500 mg twice daily or to receive a placebo for 12 weeks. Outcome measured included the occurrence of GDM and other perinatal outcomes. Between 2020 and 2022, 276 participants were enrolled, with 139 in the DCI Group and 137 in the Control Group. Occurrence of GDM was significantly lower in the DCI group compared to that in placebo group (24.8% vs. 38.1%, p = 0.027). A significant difference was observed in the 1-h glycemia during the oral glucose tolerance test (OGTT) (8.35 ± 1.55 vs. 8.81 ± 1.85, p = 0.043), however, no significant differences in the fasting glucose level or 2-h glycemia between the two groups. The mean birth weight of newborns in the control group was significantly heavier than in the DCI group (3487.9 ± 437.7 g vs. 3341.6 ± 420.1 g, p = 0.011). Therefore, DCI supplementation in early pregnancy can reduce the occurrence of GDM in women at high risk. Trial Registration: ClinicalTrials.gov identifier: NCT 04801485.

Self-monitoring of blood glucose (SMBG) is the standard of care for women with gestational diabetes mellitus (GDM). This study aimed to review SMBG profiles in women with GDM and to examine how glucose metrics derived from SMBG relate to fetal overgrowth and infants born large for gestational age (LGA, >90th percentile).

This was a single-center, historical, observational cohort study of 879 GDM pregnancies in Sweden. The diagnosis of GDM was based on a universal 75 g oral glucose tolerance test at gestational week 28 or 12 in high-risk women. The glucose metrics derived from the SMBG profiles were calculated. Treatment targets for glucose were <5.3 mmol/L fasting, and ≤7.8 mmol/L 1-h postprandial. The median (interquartile range) number of glucose measurements in the analysis for each woman was 318 (216-471), including 53 (38-79) fasting glucose measurements. Associations between glucose metrics and LGA were analyzed using binary logistic regression analysis adjusted for maternal age, body mass index, smoking, nulliparity, and European/non-European origin. Receiver operating characteristic (ROC) curves were used to evaluate glucose levels for LGA prediction. Differences in means were tested using analysis of variance.

The proportion of LGA infants was 14.6%. Higher mean glucose levels and smaller proportion of readings in target (glucose 3.5-7.8 mmol/L) were significantly associated with LGA (odds ratio [95% confidence interval]: 3.06 [2.05-4.57] and 0.94 [0.92-0.96], respectively). The strongest association was found with mean fasting glucose (3.84 [2.55-5.77]). The ability of mean fasting glucose and overall mean glucose to predict LGA infants in the ROC curves was fair, with areas under the curve of 0.738 and 0.697, respectively (p < 0.001). The corresponding discriminating thresholds were 5.3 and 6.1 mmol/L, respectively. Mean glucose levels increased and readings in target decreased with increasing body mass index category and at each step of adding pharmacological treatment, from diet alone to metformin and insulin (p < 0.001).

Higher mean glucose levels and a smaller proportion of readings within the target range were associated with an increased risk of LGA. Suboptimal glucose control is associated with obesity and the need for pharmacological treatment.

This study investigates the association between a new insulin resistance indicator, the triglyceride-glucose (TyG) index, and the risk of macrosomia.

This is a prospective cohort study.

This study included 1332 women who delivered at Peking University International Hospital between October 2017 and August 2019. Participants were divided equally into three groups based on the TyG index. Logistic regression and restricted cubic spline (RCS) analyses were used to evaluate the relationship between the TyG index and macrosomia and conducted subgroup analyses. The TyG index's ability to predict macrosomia was assessed using the receiver operating characteristic (ROC) curve.

Multivariable logistic regression analysis revealed that the TyG index is an independent risk factor for macrosomia (Odds ratio [OR] 1.84, 95% confidence interval [CI] 1.02-3.30, p < .05). RCS analysis indicates that the risk of macrosomia increases with the rise of the TyG index (p for nonlinearity <.001) when the TyG index is >6.53. Subgroup analysis showed a synergistic additive interaction between the TyG index and gestational diabetes mellitus (GDM) of macrosomia. The area under the ROC curve for the predictive model was 0.733 (95% CI 0.684, 0.781), with a sensitivity of 76.4% and specificity of 66.9%. Incorporating the TyG index alongside traditional risk factors notably enhances macrosomia prediction (p < .05).

The TyG index independently predicts macrosomia, and exhibits an additive interaction with GDM in its occurrence. Integrating the TyG index with traditional risk factors improves the prediction of macrosomia.

Clinical trials. gov [NCT02966405].

Gestational diabetes mellitus (GDM) represents a significant metabolic disorder that affects pregnant women worldwide and has negative consequences for both the mother and her offspring. This research aims to investigate the relation between circulating levels of Galectin-3 and the incidence of GDM, and to evaluate its potential as a biomarker for monitoring and early detection of the disease.

A thorough search of the literature has been performed using databases such as Scopus, Web of science, Embase, Cochrane Library and PubMed. The standardized mean difference (SMD) and corresponding confidence intervals (CIs) were used to compute the effect size from individual records and pooled using the Random-effect model.

Our meta-analysis synthesized data from 9 studies, encompassing 1,286 participants (533 GDM patients and 753 healthy pregnant controls). The findings demonstrated a considerable increase in Galectin-3 levels among individuals diagnosed with GDM as compared to the healthy control (SMD = 0.929; CI: 0.179-1.679; p = 0.015), with observed heterogeneity (I2 = 87%; p < 0.001). Subgroup analyses revealed the influence of factors such as age, BMI, study design, and sample type on Galectin-3 levels. A meta-regression analysis further identified trends indicating that levels of Galectin-3 are linked to gestational age, specific geographical areas, and sample size.

Increased levels of Galectin-3 exhibit a significant association with GDM, indicating its prospective utility as a biomarker for early detection and risk assessment. Further research is warranted to elucidate its regulation and clinical implications in GDM management.

The online version contains supplementary material available at 10.1007/s40200-024-01461-z.

Few studies have examined associations between maternal epigenetic age acceleration and adverse birth outcomes, and none have investigated paternal epigenetic age acceleration. Our objective was to assess the associations of parental (both maternal and paternal) epigenetic age acceleration in relation to birth outcomes.

Parental epigenetic age was estimated using seven established epigenetic clocks in 2198 mothers and 2193 fathers from the Norwegian Mother, Father, and Child Cohort Study (MoBa). Individual epigenetic age acceleration was then calculated as residuals from linear regressions of estimates from the epigenetic clocks on chronological age. Further, linear regression was used to analyze differences in continuous outcomes (gestational length and standardized birthweight), while logistic regression was used for binary outcomes (preterm birth, post-term birth, small-for-gestational age [SGA], large-for-gestational age [LGA], and pre-eclampsia), adjusting for chronological age, parity, educational level, smoking, and BMI.

Increasing maternal, but not paternal, epigenetic age acceleration was associated with decreased gestational length for five out of six clocks, with adjusted estimates ranging from a mean 0.51-day decrease (95% CI - 1.00, - 0.02; p-value 0.043) for the Horvath clock to a 0.80-day decrease (95% CI - 1.29, - 0.31; p-value 0.002) for the Levine clock. An association with increasing maternal epigenetic age acceleration according to the DunedinPACE clock was also seen with greater standardized birthweight [mean difference 0.08 (95% CI 0.04, 0.12; p-value < 0.001]. These results were also reflected in an increased risk of spontaneous preterm birth and LGA. No associations were observed with post-term birth, SGA, or pre-eclampsia.

Maternal, but not paternal, epigenetic age acceleration is associated with shorter pregnancies and an increased risk of spontaneous preterm birth. This may suggest that women's biological age acceleration, including factors such as metabolic and physiologic state, is an additional risk factor for preterm delivery, beyond chronological age.

To investigate the positive rate of late-onset gestational diabetes mellitus (GDM) by additional fasting blood glucose (FBG) screening at 32-34 gestational weeks (GW) and analyse the perinatal outcomes of late-onset GDM after standard treatment.

An Prospective cohort study.

Single centre in China.

1130 singleton pregnancies with negative GDM screening in their first and second trimester.

Additional FBG testing was performed at 32-34 GW. Pregnancies with FBG ≥5.1 mmol/L were diagnosed as GDM and received standardized treatment. Perinatal outcomes were collected and compared.

Diagnosis of late-onset GDM, obstetric and neonatal outcomes.

6.3% (71/1130) of participants had FBG values ≥5.1 mmol/L and were diagnosed with late-onset GDM. Sixty-five (91.5%) were treated by dietary therapy and 6 (8.5%) by insulin therapy. The perinatal outcomes of full-term delivery were compared. The incidence of macrosomia (22.7% vs. 5.1%, adjusted odds ratio (aOR) 5.51, 95% confidence interval (CI) 1.83-16.61, p = 0.002) and NICU transferring (18.3% vs. 10.1%, aOR 1.94, 95% CI 1.01-3.74, p = 0.046) was significantly higher in late-onset GDM group than that in FBG <5.1 mmol/L group. Elevated FBG was associated with overweight or obesity during pregnancy (54.9% vs. 34.9%, OR 2.27, 95% CI 1.40-3.68, p = 0.001).

6.3% of singleton pregnancies with normal GDM screening results in the first and second trimester were found to have late-onset GDM by additional FBG screening at 32-34 GW, and their risk of macrosomia during a full-term pregnancy remains significantly higher after standard treatment.

The current diagnostic criteria for gestational diabetes (GDM) were based on data from women after 24 weeks of gestation, but this may not be equally applicable for earlier gestation. There is insufficient data regarding early pregnancy glycaemia and the associated complications. We retrospectively reviewed 39,483 deliveries and 12,918 with risk factors for GDM underwent oral glucose tolerance test (OGTT) before 24 weeks of gestation. A strong and progressively positive association was observed with any pregnancy complications in both fasting glucose (FG) and 2 h glucose (2hG). The increased risk of developing any pregnancy complications started from FG 4.5-4.7 mmol/L and 2hG of 6.2-6.9mmol/L. Every increase by 1 mmol/L in FG or 2 hG levels increased the risk of developing any complications (aOR 1.614 for FG and 1.131 for 2hG), pre-eclampsia (aOR 1.472 for FG and 1.143 for 2hG), maternal insulin use (aOR 12.821 for FG and 2.366 for 2hG), primary Caesarean section(aOR 1.274 for FG and 1.099 for 2hG), shoulder dystocia (aOR 1.941 for FG and 1.282 for 2hG), macrosomia(aOR 2.203 for FG and 1.072 for 2hG), and large for gestation age(aOR 2.157 for FG and 1.074 for 2hG). Therefore, glycaemic levels in early pregnancy among high-risk women positively associated with pregnancy complications, even at levels below the current recommended diagnostic criteria for GDM.

Previous animal studies found beneficial effects of choline and betaine on maternal glucose metabolism during pregnancy, but few human studies explored the association between choline or betaine intake and incident gestational diabetes mellitus (GDM). We aimed to explore the correlation of dietary choline or betaine intake with GDM risk among Chinese pregnant women. A total of 168 pregnant women with GDM cases and 375 healthy controls were enrolled at the Seventh People's Hospital in Shanghai during their GDM screening at 24-28 gestational weeks. A validated semi-quantitative FFQ was used to estimate choline and betaine consumption through face-to-face interviews. An unconditional logistic regression model was adopted to examine OR and 95 % CI. Compared with the controls, those women with GDM incidence were likely to have higher pre-pregnancy BMI, be older, have more parities and have higher plasma TAG and lower plasma HDL-cholesterol. No significant correlation was observed between the consumption of choline or betaine and incident GDM (adjusted OR (95 % CI), 0·77 (0·41, 1·43) for choline; 0·80 (0·42, 1·52) for betaine). However, there was a significant interaction between betaine intake and parity on the risk of GDM (Pfor interaction = 0·01). Among those women with no parity history, there was a significantly inverse correlation between betaine intake and GDM risk (adjusted OR (95 % CI), 0·25 (0·06, 0·81)). These findings indicated that higher dietary betaine intake during pregnancy might be considered a protective factor for GDM among Chinese women with no parity history.

Obesity, gestational diabetes mellitus (GDM), and bariatric metabolic surgery (BMS) are increasingly common conditions during pregnancy.

However, clinical knowledge regarding GDM that occurs after BMS remains full of uncertainties. Given its prevalence and potential consequences for the dyad pregnant and offspring, it is imperative to increase knowledge about GDM after BMS, define diagnostic criteria and consequently strategies capable of improving pregnancy outcomes.

This paper aimed to review GDM screening methods after BMS and gives insights regarding new paths of research on this paramount obstetric condition.

Ethnic differences associated with oral glucose tolerance test (OGTT) phenotypes is less studied in Southeast Asian ethnicities, especially in women with hyperglycemia in pregnancy (HIP).

We retrospectively examined 3027 women at KK Women's and Children's Hospital in 2019. Of these, 508 (16.8%) women were diagnosed with HIP using the IADPSG (International Association of Diabetes and Pregnancy Study Groups) criteria at 24-28 weeks. OGTT phenotypes were classified into four mutually exclusive groups based on abnormal plasma glucose at (1) 0 hour only; (2) 1 hour only; (3) 2 hour only; (4) ≥2 timepoints (reference). Multinomial logistic regression was used to examine the association between ethnicity and OGTT phenotypes, adjusting for maternal age, parity, and first-trimester body mass index.

Overall HIP prevalence was 16.8%, highest among Indians (20.5%), then Chinese (18.3%) and Malays (14.2%). Indians (relative risk ratio (RRR) 3.05) and Chinese (RRR 2.33) were at higher risk of displaying a fasting-only phenotype compared with Malays. Chinese were at increased risk of displaying a 2-hour postprandial phenotype with an RRR of 2.88 as compared with Malays.

Unique OGTT phenotypes exist across ethnic groups among women who developed HIP in a multi-ethnic Asian population.

Gestational diabetes mellitus (GDM) is a common complication of pregnancy that can lead to adverse outcomes. In this retrospective cohort study, maternal fasting blood sugar (FBS) in the second trimester of pregnancy, body mass index (BMI), and age were assessed as potential screening indicators of later GDM.

The study population included information on 4007 Iranian pregnant women documented by the Integrated Health Record System (SIB) record system (2019-2020).

In the adjusted analysis, FBS maintained a significant relationship with GDM (P ≤0.001). In the simple ROC analysis, the AUC (SE) of FBS for the prediction of GDM was 0.905(0.09), and considering the cut-off point as 85.95, sensitivity (Se) and specificity (Sp) were equal to 0.81 and 0.71, respectively, but by stillbirth, abortion, prematurity, neonatal weight, height, and head circumference not obtained acceptable AUC (≥.60) for detection of FBS cut-off point. The cut-off point of FBS in the presence of maternal age (AUC>0.6) and BMI (AUC>0.6) by GDM was 83.75(Se= 86.4%, Sp= 80.0%).

Based on the evidence presented, maternal weight and BMI are important in predicting hyperglycemia leading to GDM. It is necessary to conduct more precise national studies to standardize the FBS cut-off point by controlling age and BMI variables.

Previous studies have shown that higher hemoglobin A1c (HbA1c) levels within the normal range during pregnancy can increase the risk of adverse birth outcomes. However, the effects of the longitudinal HbA1c trajectory during pregnancy on adverse birth outcomes among non-gestational diabetic women are poorly characterized. We aimed to identify HbA1c trajectory during pregnancy among non-gestational diabetic women and to estimate their associations with adverse birth outcomes.

Data was extracted from the Information System of Guangdong Women and Children Hospital, China, from January 2017 to July 2022. This study involved 13,979 women who did not have gestational diabetes mellitus and underwent repeated HbA1c measurements during pregnancy. Latent mixture modeling was used to identify HbA1c trajectory groups. Logistic regression was applied to explore the associations between HbA1c trajectory groups and adverse birth outcomes, including preterm delivery, low birth weight, macrosomia, small for gestational age, and large for gestational age (LGA).

Three HbA1c trajectory groups were identified: low-stable (range 4.0% [20 mmol/mol]-4.4% [25 mmol/mol]), moderate-stable (range 4.6% [27 mmol/mol]-5.1% [32 mmol/mol]), and elevated-increasing (range 5.0% [31 mmol/mol]-5.6% [38 mmol/mol]). Compared with the low-stable HbA1c group, the elevated-increasing group had a higher risk of preterm delivery and LGA. The adjusted OR (95% CIs) were 1.67 (1.13, 2.49) and 1.47 (1.01, 2.12) for preterm delivery and LGA, respectively.

Among non-gestational diabetic women, the elevated-increasing HbA1c trajectory group was associated with a higher risk of preterm delivery and LGA. This finding emphasizes the importance of maintaining optimal HbA1c levels throughout pregnancy.

Gestational diabetes mellitus (GDM) is a complication of abnormal glucose tolerance during pregnancy, with incidence is on the rise. There are inconsistent results on the risks of GDM and it has not been reported in our region. The purpose of this study is to explore the risk factors of GDM.

A total of 383 pregnant women were analyzed, including 67 (17.5%) pregnant women with GDM and 316 (82.5%) with normal glucose tolerance (NGT). The relationship of personal history, family history and reproductive history of pregnant women, the levels of alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), inflammatory markers in blood cell analysis at the first prenatal examination, and fetal ultrasound indices and the risk of GDM were analyzed.

The fetal biparietal diameter, head circumference, and femur length were negatively correlated with HCG level, but not inflammatory markers. The proportion of pregnant women aged ≥30 years old, body mass index (BMI) in early pregnancy≥24.0 kg/m2, history of polycystic ovary syndrome (PCOS), cesarean section, adverse pregnancy, and oral contraceptive use, and pregnant women who conceived through assisted reproduction in GDM group were higher than those in NGT group. Logistic regression analysis showed that age of pregnant woman ≥30 years old (≥30 vs <30 years old, odds ratio (OR): 2.142, 95% confidence interval (CI): 1.183-3.878, p=0.012), BMI≥24.0 kg/m2 (≥24.0 kg/m2 vs 18.5-23.9 kg/m2, OR: 1.887, 95% CI: 1.041-3.420, p=0.036), history of adverse pregnancy (yes vs no, OR: 1.969, 95% CI: 1.022-3.794, p=0.043), and history of oral contraceptive use (yes vs no, OR: 2.868, 95% CI: 1.046-7.863, p=0.041) were associated with GDM.

Age of pregnant woman ≥30 years old, BMI≥24.0 kg/m2, history of adverse pregnancy and oral contraceptive use were independent risk factors for GDM.

Gestational diabetes is associated with adverse outcomes such as preterm birth (<37 weeks). However, there is no international consensus on screening criteria or diagnostic levels for gestational diabetes, and it is unknown whether body mass index (BMI) or obesity modifies the relation between glucose level and preterm birth.

We studied a pregnancy cohort restricted to two Danish regions from the linked Danish Medical Birth Register to study associations between glucose measurements from the 2-hour postload 75-g oral glucose tolerance test (one-step approach) and preterm birth from 2004 to 2018. In Denmark, gestational diabetes screening is a targeted strategy for mothers with identified risk factors. We used Poisson regression to estimate rate ratios (RR) of preterm birth with z-standardized glucose measurements. We assessed effect measure modification by stratifying analyses and testing for heterogeneity.

Among 11,337 pregnancies (6.2% delivered preterm), we observed an adjusted preterm birth RR of 1.2 (95% confidence interval [CI] = 1.1, 1.3) for a one-standard deviation glucose increase of 1.4 mmol/l from the mean of 6.7 mmol/l. There was evidence for effect measure modification by obesity, for example, adjusted RR for nonobese (BMI, <30): 1.2 (95% CI = 1.1, 1.3) versus obese (BMI, ≥30): 1.3 (95% CI = 1.2-1.5), P = 0.05 for heterogeneity.

Among mothers screened for gestational diabetes, increased glucose levels, even those below the diagnostic level for gestational diabetes in Denmark, were associated with increased preterm birth risk. Obesity (BMI, ≥30) may be an effect measure modifier, not just a confounder, of the relation between blood glucose and preterm birth risk.